Chronic viral infections and malignant tumors can cause T cells to become dysfunctional and exhausted through two different associated immune statuses: inflammation and immunosuppression. Inflammatory immunity is a necessary step for the establishment of the immune response to control infection and cancer. However, once a pathogen cannot be cleared in time or a tumor continues to progress, an immunosuppressive environment involving various immune cells and cytokines may form, thereby promoting the persistence of the pathogen or tumor. Among those immune factors, type I interferons play a dual role by driving inflammation and inducing a variety of suppressive factors that limit immune responses in chronic infection and cancer. 1 CD8 + T cells are the main effector cells that act against infection and tumors. Type I interferon signaling promotes the initial activation of CD8 + T cells, drives their cytolytic ability and is also critical for their survival. However, during chronic infection or tumor outgrowth, continued exposure to type I interferons impairs T-cell function and drives disease progression.
In addition to type I interferons, there are a variety of known extracellular factors that affect T-cell function, but the exact intrinsic mechanisms of T-cell dysfunction are still not very clear. Over the past decade, crucial immune functions, including T-cell activation, differentiation and development, were shown to be regulated by specific microRNAs (miRNAs). 2 However, the role of miRNAs in the modulation of T-cell function in chronic infection is less known. In a recent study, Moffett et al. 3 identified the microRNA miR-31 as an important regulator of T-cell function in chronic infection by increasing the sensitivity of T cells to type I interferons, which interfered with effector T-cell function and increased the expression of several proteins related to T-cell dysfunction during chronic infection (Figure 1) .
MiR-31 has been reported to be negatively correlated with the severity of systemic lupus erythematosus, 4 suggesting that the molecule might have a role in weakening the immune response.
Another study reported that miR-31 negatively regulates FOXP3 expression by binding directly to its potential target site in the 3′ UTR of FOXP3 mRNA. 5 This appeared to be another aspect of miR-31's role in the immune response, indicating that miR-31 may have the potential to enhance the immune response by disrupting the development of Treg cells. By comparing the profiling data of miRNAs in activated T cells, total thymocytes, B cells, T cells, bone marrow-derived DCs and LPS-treated DCs, Moffett et al. 3 found that miR-31 may play a special role during T-cell activation and differentiation. The expression of miR-31 increased in T cells that have an effector/memory phenotype compared to their naive counterparts. Further investigation indicated that the induction of miR-31 is dependent on the calcium-NFAT pathway downstream of TCR signaling. Similar to this finding, Xue F et al. 6 reported that miR-31 was upregulated during the activation of primary human T lymphocytes upon TCR stimulation. To investigate the genes or pathways targeted by miR-31, all mRNAs that were differentially expressed in CD8 + T cells transduced with lenti-miR-31 relative to their expression in CD8 + T cells transduced with lenti-eGFP were analyzed. The pathway analysis showed that several type I interferon pathway genes were significantly correlated with miR-31 expression. Furthermore, 13 targets were To illustrate the effect of miR-31 on T-cell responses in chronic infection, wild-type mice and Mir31 − / − mice were infected intravenously with LCMV clone 13. The initial disease course was similar in wild-type mice and Mir31 − / − mice after infection with the same LCMV strain, and Mir31 − / − mice were found to undergo a faster recovery and show better viral control. LCMV-specific CD8 + T-cell responses with effector and effector-memory phenotypes were enhanced in miR-31-deficient mice. There was no difference between the wild-type mice and Mir31 − / − mice in their central memory CD8 + T cells, CD4 + T cells and antibody responses. Their experiment failed to reproduce the inhibitory effects of miR-31 on FOXP3 expression, and they did not observe differences in the frequency of Tregs between Mir31 − / − mice and wild-type mice at baseline or at day 30 following infection with LCMV clone 13.
To exclude the possibility that miR-31 indirectly affects T cells through other cells, Mir31 fl/fl Cd4 Cre mice were also infected with LCMV clone 13, and the outcome was similar to that of Mir31 − / − mice. Functional analysis showed that Mir31 − / − mice had more functional CD8 + T cells than wild-type mice, which further validated the detrimental effect of miR-31 on T-cell function through intrinsic mechanisms.
T-cell dysfunction is responsible for the failure of immune control of chronic infection and tumors, and type I interferons play a role as one of the key nodes of the immune regulatory network. Moffett et al. 3 noted that miR-31 can increase the sensitivity of T cells to type I interferon and it may possibly be used as a target to reshape immunity to control these chronic diseases. In addition to miR-31, several other miRNAs were reported to directly regulate different aspects of the type I interferon signaling pathway. 7 For example, miR29a has been shown to reduce the expression of IFNAR.
MiR-19a, miR-122 and miR-155 have been shown to target SOCS1, resulting in the enhancement of type I interferon signaling. STAT1 is targeted by miR-145, miR-146 and miR-221/222, and STAT2 is targeted by miR-221/222, reducing type I interferon signaling. According to Moffett et al.'s data and other reports, the expression of miR-155 also increased following the activation of CD8 + T cells. Similar to miR-31, miR-155 deficiency can increase the sensitivity of CD8 + T cells to type I interferon, and anti-viral CD8 + T-cell responses and viral clearance were impaired in miR-155-deficient mice. 8 However, in another report, miR-155 was shown to be crucial for effector CD8 + T-cell accumulation, virus control in chronic LCMV infection and the inhibition of tumor growth. 9 The effects of miR-155 on CD8 + T cells were contributed to its inhibitory effect on SOCS1, which is a negative regulator of the type I interferon signaling pathway. The precise mechanisms behind the different effects of miR-31 and miR-155 on CD8 + T cells during chronic infection require further study.
